Wee Joo Chng/LinkedIn
Jun 25, 2025, 08:46
Wee Joo Chng: We Concluded Another International Myeloma Study Group Summit – The Progress Has Been Tremendous
Wee Joo Chng, Professor in Medical Oncology at the National University of Singapore, shared a post on LinkedIn:
“We concluded another International Myeloma Study Group (IMWG) Summit. Many important discussions and new initiatives, as we continue to chip away at this cancer. The progress has been tremendous.
Key highlight this year
– for patients fit for a transplant the progression free survival of a newly diagnosed patient with a quadruplet induction is now projected to be 180+ months!
– even for very relapse and refractory patients the use of BCMA CAR-T is provided progression free survival exceeding 5 years in a third of patients.
These are unprecedented. Yet we are not content. An attitude of persistent discontent is key to relentless progress.
The progress in Asia is behind due to poorer access to therapies. In the meantime, access to clinical trials is key. This is a key piece of work for the Asian Myeloma Network (AMN).
We always have a breakfast meeting in conjunction with the IMWG summit. This year there are no empty seats in the room as we plot future trials.
We also have a potentially historic meeting with our colleagues from the European Myeloma Network (EMN) (Profs Sonneveld and Boccodoro). The possibilities of East-West colllaboration between AMN and EMN fills us with excitement!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 25, 2025, 08:44
Jun 25, 2025, 08:43
Jun 25, 2025, 08:37